In a session at AMCP's 27th Annual Meeting & Expo that was so popular that attendees were being directed to an overflow room, Aimee Tharaldson, PharmD, senior clinical consultant in emerging therapeutics at Express Scripts, highlighted specialty pharmaceuticals that are currently in development and expected to come to the market in the next few years.
In a session at AMCP's 27th Annual Meeting & Expo, held April 7-10 in San Diego, that was so popular that attendees were being directed to an overflow room, Aimee Tharaldson, PharmD, senior clinical consultant in emerging therapeutics at Express Scripts, highlighted specialty pharmaceuticals that are currently in development and expected to come to the market in the next few years.
The key specialty market trends she highlighted were increased competition, orphan drug development, and breakthrough therapies. Through 2019, 30 specialty drug products have patent expirations, which represents a $14.1 billion specialty generic drug opportunity. In addition, there is a $39.1 billion biosimilar opportunity with 54 biologic products losing patent protections through 2020. In 2015 alone Neulasta, Rituxan, Epogen, Procrit, Neupogen, Synagis, and Pulmozyme all have patent expirations.
“Of course, it’s important to remember that just because they may have a patent expiration at that time does not necessarily mean we will see a biosimilar approved at that time,” she said. “There are still a lot of issues that need to be resolved, including litigation.”
Biosimilar Update
Reference biologics are given 12 years of patent protection. In addition, biosimilars cannot be submitted for another 4 years after that.
Zarxio (filgrastim) from Sandoz, biosimilar to Neupogen by Amgen, was the first biosimilar approved by the FDA for use in the United States. A number of other biosimilars have expected approval dates in 2015: Inflectra (infliximab) from Celltrion and Hospira (June 8); a pegfilgrastim biosimilar from Apotex (August 17); Grastofil (filgrastim) from Apotex (October 13); and Retacrit (epoetin alfa) from Hospira (October 16).
Initially, biosimilars will act as competing brands, according Dr Tharaldson. She expects they will be priced at a 20% discount of the branded products, but the cost to develop and market, plus pay patent attorneys will add up.
Specialty Pipeline: Cancer Drugs
More than one-third of the specialty pipeline is in development for cancer medications, and half of those are administered orally, Dr Tharaldson said.
The market is seeing more breakthrough therapies as well as continuing development of targeted therapies and immunotherapies. The latter of which is expected to treat half of cancer in the next 10 years, she added.
Specialty Pipeline: Hepatitis C
There are now all oral options available for the 3.2 million Americans with hepatitis C: Harvoni, Viekira Pak, Sovaldi, and Olysio. The standard of care for hepatitis C is evolving rapidly with guidelines being updated frequently, Dr Tharaldson said.
In addition, based on the drugs in the pipeline, there will be more oral interferon-free regimens hitting the market, but also more drugs able to treat all genotypes and shorter treatment durations.
Just that morning, Merck had received breakthrough status for grazoprevir/elbasvir, a single once-daily tablet for the treatment of genotype 1. The company is also developing grazoprevir/elbasavir with MK-3682, which would treat genotypes 1-6, although approval isn’t expected until 2018. Other drugs being developed to treat all genotypes are Gilead’s GS-5816/Sovaldi (approval in 2016); Achillion’s ACH-3102/ACH-3422 (approval in 2017); and AbbVie’s ABT-493/ABT-530 (approval in 2018).
Specialty Pipeline: Hypercholesterolemia
The 71 million Americans with high LDL-cholesterol are typically treated with statins, but 10 million patients have statin intolerance or do not reach their LDL-cholesterol goal.
There are 2 PCSK9 inhibitors expected to be approved this summer: Praluent from Sanofi/Regeneron (July 24) and Repatha from Amgen (August 27).
“This is going to be the most important area to keep an eye on this year,” Dr Tharaldson said.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More